Next Phase Newsletter

A strategic corporate venture capital fund of an oncology pharmaceutical company seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the corporate’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the corporate’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in USA actively makes equity investments in early stage biotechnology companies with typical allocations of about $20-50M per company. The firm will consider investing in researchers located worldwide but typically create companies anywhere in the US where there is strong biology/biotech talent, inclusive but not limited to San Francisco, San Diego, Seattle, Dallas, NY, and Boston. The firm would only build/invest in a company elsewhere in exceptional circumstances.  The firm only considers opportunities in which they can participate in the first round of institutional investment.

The firm is seeking to build drug discovery and development companies, and prefers to invest at or before the preclinical stage; the firm is open to investing in concept-stage technologies that do not yet have protected IP.  The firm focuses on novel biology; the firm will consider investments in any disease area and is open to investing in any therapeutic technology provided the potential application of the technology has been established.  Only therapeutic technologies are of interest; devices and diagnostics will not be considered.

The firm typically engages prior to company formation.  The firm is a very hands-on investor and will take an active role in management recruitment and company-building.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An equity investment firm with an investment bank has an active investment strategy that promotes company development (operations, sales, partnerships, etc.). The firm considers a broad range of sectors, including life science and healthcare with a particular interest in software and consumer products. The firm typically leads investments but does not invest in startups. The firm invests on a global level, and seeks companies based all over the world.

The firm is open to all opportunities in healthcare IT, diagnostics, medical devices of all classes, and laboratory equipment. The firm is particularly interested in technology involving software, though is not open to biotech therapeutics because of the longer timeline to commercialization. However, the firm is very interested in (nuclear) radiopharmaceuticals. The firm is interested in late-stage companies that are generating revenue with positive cash-flow.

The firm will typically provide guidance and leadership support after an investment, and would support the company with future endeavors, including joint ventures and licensing partnerships. The firm would take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a fully integrated healthcare solution provider that was founded in 1993 and is headquartered in Wuhan, China. The firm is leading in several market segments in Asia, including family planning medicines, anesthesia, Uyghur medicines, traditional Chinese medicines, medicines for central nervous system, bio-medicines and others. The group is seeking in-licensing, acquisition, and partnership opportunities based in China and North America. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The group can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion.

The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the group is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The group seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.

The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The group typically seeks board representation after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The company is a global biotech company founded in 1929 and headquartered in Europe. The Company has three R&D facilities in the US, the UK, and France. The Company has several marketed products in oncology, rare diseases, and neurosciences and has global commercial and development capabilities. The firm is actively seeking to expand its pipeline by working with early stage biotechs and academic groups. The Company is open to a variety of deal structures and seeks to construct deals that maximize the potential of the therapeutic program by leveraging the capabilities of all partners involved while meeting the needs of the entrepreneur/startup. The Company is also an anchor investor in a newly launched venture fund that will have an associated accelerator which will start / fund project focused companies to work in close partnership with company R&D. This fund will add additional flexibility in the firm’s ability to work with the early stage biotech and academic communities.

The Company is focused on enhancing its pipeline with oncology, rare disease, and select neuroscience drug assets. The firm is interested in highly differentiated late stage pre-clinical and clinical stage therapeutic candidates with strong scientific rationale targeting indications with significant unmet medical need.

The firm has no strict requirements for companies or management teams and looks to work creatively and collaboratively on partnerships with early-stage companies. The firm is open to opportunities/companies on a global basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm that was founded in 2000 and is based in Missouri, with an additional office in Ohio. As of 2015, the firm had assets under management of $283 million. Since inception, the firm has raised three investment funds with total committed capital of $247 million. The most-recent fund closed in early 2015, with commitments of $80 million. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $12 million throughout a portfolio company’s path to liquidity.

The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.

The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A newly established venture capital firm was founded in 2020 and is based in San Francisco, CA. The firm is expecting to close their first fund this year, targeting $100M. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Israel, Japan, Europe, Asia, etc.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech-enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. Kicker Ventures likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.